205 related articles for article (PubMed ID: 37513350)
1. [1,2,4]triazolo[4,3-
Patinote C; Raevens S; Baumann A; Pellegrin E; Bonnet PA; Deleuze-Masquéfa C
Molecules; 2023 Jul; 28(14):. PubMed ID: 37513350
[TBL] [Abstract][Full Text] [Related]
2. Imidazo[1,2-
Chouchou A; Patinote C; Cuq P; Bonnet PA; Deleuze-Masquéfa C
Molecules; 2018 Nov; 23(11):. PubMed ID: 30445763
[TBL] [Abstract][Full Text] [Related]
3. Imidazo[1,2-a]quinoxalines for melanoma treatment with original mechanism of action.
Patinote C; Deleuze-Masquéfa C; Kaddour KH; Vincent LA; Larive R; Zghaib Z; Guichou JF; Assaf MD; Cuq P; Bonnet PA
Eur J Med Chem; 2021 Feb; 212():113031. PubMed ID: 33309473
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives.
Moarbess G; Deleuze-Masquefa C; Bonnard V; Gayraud-Paniagua S; Vidal JR; Bressolle F; Pinguet F; Bonnet PA
Bioorg Med Chem; 2008 Jul; 16(13):6601-10. PubMed ID: 18513976
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of [1,2,4]triazolo[4,3-a]quinoxaline-1,3,4-oxadiazole derivatives as potent antiproliferative agents via a hybrid pharmacophore approach.
Kaneko D; Ninomiya M; Yoshikawa R; Ono Y; Sonawane AD; Tanaka K; Nishina A; Koketsu M
Bioorg Chem; 2020 Nov; 104():104293. PubMed ID: 33010622
[TBL] [Abstract][Full Text] [Related]
6. New imidazo[1,2-a]quinoxaline derivatives: synthesis and in vitro activity against human melanoma.
Deleuze-Masquefa C; Moarbess G; Khier S; David N; Gayraud-Paniagua S; Bressolle F; Pinguet F; Bonnet PA
Eur J Med Chem; 2009 Sep; 44(9):3406-11. PubMed ID: 19278757
[TBL] [Abstract][Full Text] [Related]
7. Facile synthesis of C6-substituted benz[4,5]imidazo[1,2-a]quinoxaline derivatives and their anticancer evaluation.
Singh R; Kumar R; Pandrala M; Kaur P; Gupta S; Tailor D; Malhotra SV; Salunke DB
Arch Pharm (Weinheim); 2021 Jul; 354(7):e2000393. PubMed ID: 33749032
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of the cytotoxic activity of novel ethyl 4-[4-(4-substitutedpiperidin-1-yl)]benzyl-phenylpyrrolo[1,2-a]quinoxaline-carboxylate derivatives in myeloid and lymphoid leukemia cell lines.
Desplat V; Vincenzi M; Lucas R; Moreau S; Savrimoutou S; Pinaud N; Lesbordes J; Peyrilles E; Marchivie M; Routier S; Sonnet P; Rossi F; Ronga L; Guillon J
Eur J Med Chem; 2016 May; 113():214-27. PubMed ID: 26945110
[TBL] [Abstract][Full Text] [Related]
9. Quinoxaline-1,4-dioxide derivatives inhibitory action in melanoma and brain tumor cells.
Silva L; Coelho P; Soares R; Prudêncio C; Vieira M
Future Med Chem; 2019 Apr; 11(7):645-657. PubMed ID: 30964331
[No Abstract] [Full Text] [Related]
10. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
El-Adl K; El-Helby AA; Sakr H; Elwan A
Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
[TBL] [Abstract][Full Text] [Related]
11. Liquid chromatography-electrospray ionization-tandem mass spectrometry method for quantitative estimation of new imiqualine leads with potent anticancer activities in rat and mouse plasma. Application to a pharmacokinetic study in mice.
Chouchou A; Marion B; Enjalbal C; Roques C; Cuq P; Bonnet PA; Bressolle-Gomeni FMM; Deleuze-Masquéfa C
J Pharm Biomed Anal; 2018 Jan; 148():369-379. PubMed ID: 29111492
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors.
Ibrahim MK; Taghour MS; Metwaly AM; Belal A; Mehany ABM; Elhendawy MA; Radwan MM; Yassin AM; El-Deeb NM; Hafez EE; ElSohly MA; Eissa IH
Eur J Med Chem; 2018 Jul; 155():117-134. PubMed ID: 29885574
[TBL] [Abstract][Full Text] [Related]
13. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH
Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640
[TBL] [Abstract][Full Text] [Related]
14. Quinoxaline-Based Scaffolds Targeting Tyrosine Kinases and Their Potential Anticancer Activity.
El Newahie AM; Ismail NS; Abou El Ella DA; Abouzid KA
Arch Pharm (Weinheim); 2016 May; 349(5):309-26. PubMed ID: 27062086
[TBL] [Abstract][Full Text] [Related]
15. Molecular modeling studies and synthesis of novel quinoxaline derivatives with potential anticancer activity as inhibitors of c-Met kinase.
Abbas HA; Al-Marhabi AR; Eissa SI; Ammar YA
Bioorg Med Chem; 2015 Oct; 23(20):6560-72. PubMed ID: 26420384
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment.
Ali I; Lee J; Go A; Choi G; Lee K
Bioorg Med Chem Lett; 2017 Oct; 27(20):4606-4613. PubMed ID: 28939121
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of the antiproliferative activity of novel isoindolo[2,1-a]quinoxaline and indolo[1,2-a]quinoxaline derivatives.
Desplat V; Moreau S; Belisle-Fabre S; Thiolat D; Uranga J; Lucas R; de Moor L; Massip S; Jarry C; Mossalayi DM; Sonnet P; Déléris G; Guillon J
J Enzyme Inhib Med Chem; 2011 Oct; 26(5):657-67. PubMed ID: 21250818
[TBL] [Abstract][Full Text] [Related]
18. Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors.
Patinote C; Bou Karroum N; Moarbess G; Deleuze-Masquefa C; Hadj-Kaddour K; Cuq P; Diab-Assaf M; Kassab I; Bonnet PA
Eur J Med Chem; 2017 Sep; 138():909-919. PubMed ID: 28750313
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma.
Khier S; Deleuze-Masquéfa C; Moarbess G; Gattacceca F; Margout D; Solassol I; Cooper JF; Pinguet F; Bonnet PA; Bressolle FM
Eur J Pharm Sci; 2010 Jan; 39(1-3):23-9. PubMed ID: 19854270
[TBL] [Abstract][Full Text] [Related]
20. 4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
Sarges R; Howard HR; Browne RG; Lebel LA; Seymour PA; Koe BK
J Med Chem; 1990 Aug; 33(8):2240-54. PubMed ID: 2374150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
